Oxford Pharmascience’s OXPzero Ibuprofen can act faster in a human study compared to its bioequivalent

Oxford Pharmascience’s interim PK study showed that the technolology modifications can not only make OXPzero Ibuprofen bioequivalent to OTC Nurofen, but also potentially faster acting, the drugmaker said in an update on OXPzero Ibuprofen clinical program, for which on January 17, it kicked off dosing healthy patients in the first phase of the study.

Read more

Anti-inflammatory pills tied to heart failure risk

(Reuters Health) – Widely used non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of heart failure – even in people without a history of cardiac issues, a recent study suggests.

Read more